Chemed Reports Third-Quarter 2026 Results
Chemed reported Q3 2026 revenue of $690.9 million, up 10.6% year-over-year, with GAAP diluted EPS of $5.45 (+22.2%) and adjusted diluted EPS of $6.75 (+28.1%). The VITAS hospice segment drove the beat with net patient revenue up 12.2% to $457.4 million on 9.4% ADC growth, and adjusted EBITDA ex-Medicare Cap up 31.4% to $92.5 million; Roto-Rooter revenue rose 7.5% but adjusted EBITDA fell 2.5% on margin compression.
Key figures
- Eps
- 5.45
- Revenue
- 690940000
- Guidance
- Full-year 2026 adjusted EPS expected at or slightly above the high end of prior guidance issued July 28, 2026
- Revenue Yoy
- 10.6%
- Cash
- 48400000
- Vitas adc
- 24428
- Q3 buyback
- $66.0 million (125,000 shares at $528.24 avg)
- Adjusted eps
- 6.75
- Q3 net income
- 71648000
- Vitas adc yoy
- 9.4%
- Long term debt
- 236000000
- Adjusted eps yoy
- 28.1%
- Vitas revenue yoy
- 12.2%
- Roto rooter revenue
- 233500000
- Roto rooter ebitda yoy
- -2.5%
- Roto rooter revenue yoy
- 7.5%
- Vitas net patient revenue
- 457400000
- Roto rooter adjusted ebitda
- 48200000
- Remaining buyback authorization
- 73700000
- Vitas adjusted ebitda ex medicare cap
- 92500000
- Vitas adjusted ebitda margin ex medicare cap
- 20.2%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.